Vantia Therapeutics announces Positive Results from its Phase III EQUINOC®

Vantia Therapeutics announces Positive Results from its Phase III EQUINOC®

Date
October 5, 2017

Southampton, UK, 3 October 2017 – Vantia Therapeutics announces positive top-line data from a pivotal Phase III trial investigating the efficacy and safety of fedovapagon (VA106483) in the treatment of nocturia in men with benign prostatic hyperplasia (BPH) (the "EQUINOC" study). The EQUINOC trial is a 432-patient randomised, double-blind, placebo-controlled, multi-centre study conducted in the US. Patients were randomised to receive fedovapagon or placebo orally each evening over a 12-week treatment period.

Novo Holdings uses cookies to ensure that we give you the best experience on our website. Read more